{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:21:06Z","timestamp":1770236466311,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01597-7","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:27:40Z","timestamp":1764991660000},"page":"679-686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Empathy for the Patient with Chronic Hand Eczema"],"prefix":"10.1007","volume":"16","author":[{"given":"Monique","family":"Tooks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-8308","authenticated-orcid":false,"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"issue":"5","key":"1597_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/cod.14035","volume":"86","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357\u201378.","journal-title":"Contact Dermatitis"},{"key":"1597_CR2","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v101.432","volume":"102","author":"AN Voorberg","year":"2022","unstructured":"Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and severity of hand eczema in the Dutch general population: a cross-sectional, questionnaire study within the Lifelines cohort study. Acta Derm Venereol. 2022;102:adv00626.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1597_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/cod.13804","volume":"84","author":"AS Quaade","year":"2021","unstructured":"Quaade AS, Simonsen AB, Halling AS, Thyssen JP, Johansen JD. Prevalence, incidence, and severity of hand eczema in the general population\u2014a systematic review and meta-analysis. Contact Dermatitis. 2021;84(6):361\u201374.","journal-title":"Contact Dermatitis"},{"issue":"6","key":"1597_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/bjd\/ljaf020","volume":"192","author":"C Apfelbacher","year":"2025","unstructured":"Apfelbacher C, Bewley A, Molin S, et al. Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60 000 respondents from the general population of Canada, France, Germany, Italy, Spain and the UK. Br J Dermatol. 2025;192(6):1047\u201354.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1597_CR5","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/1346-8138.12088","volume":"40","author":"M Yu","year":"2013","unstructured":"Yu M, Kim SW, Kim MS, Han TY, Lee JH, Son SJ. Clinical study of patients with hand eczema accompanied by nail dystrophy. J Dermatol. 2013;40(5):406\u20137.","journal-title":"J Dermatol"},{"issue":"5","key":"1597_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/ced.12584","volume":"40","author":"N Milanesi","year":"2015","unstructured":"Milanesi N, D\u2019Erme AM, Gola M. Nail improvement during alitretinoin treatment: three case reports and review of the literature. Clin Exp Dermatol. 2015;40(5):533\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1597_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s12325-019-01164-5","volume":"37","author":"L Grant","year":"2020","unstructured":"Grant L, Seiding Larsen L, Burrows K, et al. Development of a conceptual model of chronic hand eczema (CHE) based on qualitative interviews with patients and expert dermatologists. Adv Ther. 2020;37(2):692\u2013706.","journal-title":"Adv Ther"},{"issue":"4","key":"1597_CR8","first-page":"CD004055","volume":"4","author":"WA Christoffers","year":"2019","unstructured":"Christoffers WA, Coenraads PJ, Svensson A, et al. Interventions for hand eczema. Cochrane Database Syst Rev. 2019;4(4):CD004055.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1597_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/cod.12590","volume":"75","author":"K Politiek","year":"2016","unstructured":"Politiek K, Oosterhaven JA, Vermeulen KM, Schuttelaar ML. Systematic review of cost-of-illness studies in hand eczema. Contact Dermatitis. 2016;75(2):67\u201376.","journal-title":"Contact Dermatitis"},{"issue":"1","key":"1597_CR10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/ddg.12570","volume":"13","author":"TL Diepgen","year":"2015","unstructured":"Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1-22.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"1597_CR11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/j.1365-2133.2011.10427.x","volume":"165","author":"M Augustin","year":"2011","unstructured":"Augustin M, Kuessner D, Purwins S, Hieke K, Posthumus J, Diepgen TL. Cost-of-illness of patients with chronic hand eczema in routine care: results from a multicentre study in Germany. Br J Dermatol. 2011;165(4):845\u201351.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1597_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cod.12130","volume":"70","author":"PA Cortesi","year":"2014","unstructured":"Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158\u201368.","journal-title":"Contact Dermatitis"},{"issue":"2","key":"1597_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2340\/00015555-1632","volume":"94","author":"C Apfelbacher","year":"2014","unstructured":"Apfelbacher C, Molin S, Weisshaar E, et al. Characteristics and provision of care in patients with chronic hand eczema: updated data from the CARPE registry. Acta Derm Venereol. 2014;94(2):163\u20137.","journal-title":"Acta Derm Venereol"},{"key":"1597_CR14","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2147\/TCRM.S292504","volume":"16","author":"C Dubin","year":"2020","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the treatment of chronic hand eczema: successes and key challenges. Ther Clin Risk Manag. 2020;16:1319\u201332 (Erratum in: Ther Clin Risk Manag 2021; 17: 233).","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"1597_CR15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2310\/7750.2010.09094","volume":"14","author":"C Lynde","year":"2010","unstructured":"Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267\u201384 (Erratum in: J Cutan Med Surg 2011; 15(6): 360).","journal-title":"J Cutan Med Surg"},{"issue":"4 Suppl","key":"1597_CR16","volume":"82","author":"J Fowler","year":"2008","unstructured":"Fowler J. Chronic hand eczema: diagnosis, management, and prevention of a challenging condition. Cutis. 2008;82(4 Suppl):3.","journal-title":"Cutis"},{"issue":"6","key":"1597_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/cod.12366","volume":"72","author":"A Kouris","year":"2015","unstructured":"Kouris A, Armyra K, Christodoulou C, et al. Quality of life, anxiety, depression and obsessive-compulsive tendencies in patients with chronic hand eczema. Contact Dermatitis. 2015;72(6):367\u201370.","journal-title":"Contact Dermatitis"},{"issue":"4","key":"1597_CR18","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/jid.2014.530","volume":"135","author":"FJ Dalgard","year":"2015","unstructured":"Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Investig Dermatol. 2015;135(4):984\u201391.","journal-title":"J Investig Dermatol"},{"issue":"3","key":"1597_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12840","volume":"32","author":"GR Lee","year":"2019","unstructured":"Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840.","journal-title":"Dermatol Ther"},{"issue":"7","key":"1597_CR20","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/jdv.16083","volume":"34","author":"M Tauber","year":"2020","unstructured":"Tauber M, Berard E, Lourari S, et al. Latent class analysis categorizes chronic hand eczema patients according to skin barrier impairment. J Eur Acad Dermatol Venereol. 2020;34(7):1529\u201335.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 3","key":"1597_CR21","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1610-0387.2009.07061.x","volume":"7","author":"TL Diepgen","year":"2009","unstructured":"Diepgen TL, Elsner P, Schliemann S, et al. Guideline on the management of hand eczema ICD-10 code: L20. L23. L24. L25. L30. J Dtsch Dermatol Ges. 2009;7(Suppl 3):S1\u201316.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1597_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdin.2023.11.004","volume":"14","author":"A Egeberg","year":"2024","unstructured":"Egeberg A, Schlapbach C, Haugaard JH, et al. Adverse events from topical corticosteroid use in chronic hand eczema\u2014findings from the Danish Skin Cohort. JAAD Int. 2024;14:77\u201383.","journal-title":"JAAD Int"},{"issue":"10451","key":"1597_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","volume":"404","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Warren RB, Pinter A, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase\u00a03 trials. Lancet. 2024;404(10451):461\u201373.","journal-title":"Lancet"},{"key":"1597_CR24","unstructured":"ANZUPGO\u00ae (delgocitinib) cream. Prescribing Information. LEO Pharma Inc; 2025 [accessed 2025 Aug 6]. https:\/\/www.leo-pharma.us\/AnzupgoPI."},{"key":"1597_CR25","unstructured":"Bissonnette R, Buhl T, Grewal P, et al. Patient reported outcomes and symptom improvements across subtypes of Chronic Hand Eczema: outcomes from the Phase\u00a03 DELTA-1 and DELTA-2 trials. In: Revolutionizing Atopic Dermatitis (RAD) Conference; 6\u20137 June 2025; Nashville, TN, USA."},{"key":"1597_CR26","unstructured":"Bissonnette R, Schliemann S, Gooderham M, et al. Treatment response of delgocitinib cream according to Chronic Hand Eczema (CHE) subtypes in adults with moderate to severe CHE: results from the Phase\u00a03 DELTA 1, DELTA 2, and DELTA 3 trials. In: European Academy of Dermatology and Venereology (EADV) Congress; 25\u201328 September 2024; Amsterdam, NL."},{"key":"1597_CR27","doi-asserted-by":"crossref","unstructured":"Zirwas M, Halden P, Lai Z, Kuo Y, Nawaz H, Stein Gold LF. Efficacy and safety of ruxolitinib cream for the treatment of moderate to severe chronic hand eczema: top-line results from a 16-week, multicenter, randomized, double-blind study. In: Fall Clinical Dermatology Conference; 24\u201327 October 2024; Las Vegas, NV, USA.","DOI":"10.25251\/skin.8.supp.500"},{"key":"1597_CR28","unstructured":"OPZELURA\u00ae (ruxolitinib) cream. Prescribing Information. Incyte Corporation; 2025 [accessed 2025 Aug 6]. https:\/\/www.opzelura.com\/opzelura-prescribing-information."},{"issue":"7","key":"1597_CR29","doi-asserted-by":"publisher","first-page":"702","DOI":"10.36849\/JDD.9156","volume":"24","author":"O Alani","year":"2025","unstructured":"Alani O, Shqair L, Liszewski WJ, et al. Treating chronic hand eczema with upadacitinib: insights from clinical trials and real-world experience. J Drugs Dermatol. 2025;24(7):702\u20137.","journal-title":"J Drugs Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01597-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01597-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01597-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:40:29Z","timestamp":1770190829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01597-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1597"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01597-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"6 December 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Monique Tooks declares no conflict of interest. Christopher G. Bunick has served as an investigator and\/or consultant for AbbVie, Almirall, Alumis, Amgen, Apogee, Arcutis, Botanix, Castle Biosciences, Connect BioPharma, Daiichi Sankyo, Dermavant, Eli Lilly, EPI Health\/Novan, Galderma, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Palvella, Pfizer, Regeneron, Sanofi, South Beach Symposium, Sun Pharma, Takeda, Timber, Teladoc, Triveni, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. The patient author for this paper gave their permission for the sharing of the photographs used in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}